extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
f4f0e79e10
commit
965afb6985
6 changed files with 71 additions and 1 deletions
|
|
@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP
|
|||
|
||||
The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon's 192K patient analysis shows medical cost growth drops to 2% after 12 months for GLP-1 users vs. 6% for non-users, with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This challenges the 'inflationary through 2035' thesis for long-term risk-bearers—the data suggests net savings emerge within 18-30 months for adherent users in capitated systems, though short-term payers and non-adherent populations still face inflation.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -48,6 +48,12 @@ Phase 3 trial shows semaglutide 2.4mg achieves 62.9% resolution of steatohepatit
|
|||
|
||||
FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial. The cardiovascular benefits emerged as secondary endpoints in a study designed for kidney outcomes, supporting the multi-organ protection thesis. Separate analysis in Nature Medicine showed additive benefits when combined with SGLT2 inhibitors.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon's 192K patient analysis found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations in women and 26% in men, with the sex differential suggesting larger cardiovascular benefits for women. This adds to the multi-organ protection thesis by showing substantial cardiovascular risk reduction in real-world commercial populations, not just clinical trials.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
|
|||
|
||||
No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon data shows adherence is the binding variable for GLP-1 effectiveness—the 80%+ adherent cohort shows dramatically stronger effects across all outcomes (9 percentage point lower cost growth vs. 6 points for all diabetes users; 7 points vs. 3 for weight loss users). This confirms that low persistence rates directly undermine the cost-effectiveness case because benefits scale non-linearly with adherence.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
|
|||
|
||||
The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects, but the sample is biased toward employed, insured populations. The finding that benefits require 80%+ adherence indirectly supports the affordability thesis—populations with coverage gaps or cost-sharing barriers cannot achieve the adherence levels needed for cost-effectiveness.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-16",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2026-01-13
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: report
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -49,3 +53,13 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im
|
|||
EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary.
|
||||
|
||||
flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"]
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Aon analyzed commercial health claims data from 192,000+ GLP-1 users in U.S. employer-sponsored plans
|
||||
- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs. 10% for non-users
|
||||
- After 12 months: medical costs grow 2% vs. 6% for non-users
|
||||
- For diabetes indication: medical cost growth 6 percentage points lower at 30 months; 9 points lower with 80%+ adherence
|
||||
- For weight loss indication: cost growth 3 points lower at 18 months; 7 points lower with consistent use
|
||||
- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
|
||||
- Adherent users (80%+): 47% fewer MACE hospitalizations in women, 26% in men
|
||||
|
|
|
|||
Loading…
Reference in a new issue